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To the Editor:
We thank Dr Mao and colleagues for their insightful comments and the opportunity to clarify a number of points from our work. 1 Although we considered inclusion of additional risk variables into the latent class analysis model, 1 we chose to use time changes in primary graft dysfunction (PGD) grade only to derive our classes for several reasons. First, we sought to address controversy surrounding PGD phenotypes encompassed within the International Society for Heart & Lung Transplantation defi nition based on timing of clinical PGD development. 2 , 3 Second, we did not have a large enough sample size to include all known risk factors for PGD in the model and generate stable classes. Third, using grade alone to derive the classes allowed us to demonstrate construct validity of the resultant PGD phenotypes using many of the known clinical risk factors for PGD and mortality.
We have previously published on clinical risk factors in PGD. 4 In the current study, we evaluated which of these many risk factors would distinguish between the classes. We agree that recipient BMI, for example, remains an important risk factor for PGD 5 ; however, differences in BMI did not help distinguish between those patients who will recover from injury quickly and those with persistent injury. The factors we identifi ed, including volume of blood transfusion and cardiopulmonary bypass use, may be helpful in identifying those who are at risk for graft dysfunction persisting on day 3 as well as identifying potential mechanistic links to the persistent PGD phenotype.
In the Lung Transplant Outcomes Group cohort study, subjects receiving extracorporeal membrane oxygenation (ECMO) for graft dysfunction are classifi ed as having grade 3 PGD. Therefore, we do not believe the use of ECMO in this study created a misclassifi cation bias by making it appear that subjects recovered from PGD when they did not. Additionally, only one subject in this cohort was on ECMO 72 h after transplantation, so we do not think there was signifi cant contribution from the use of ECMO.
Although our analyses generated classes that differed in time of resolution, we did include all subjects with grade 3 PGD at any time. The latent class model best defi ned classes based on resolution of lung injury, but classes based on development of injury were less apparent. However, had a class of late-onset injury been common, we believe our model would have identifi ed this pattern. We limited our study to PGD within 72 h, as that is the commonly accepted defi nition, 2 
N-Acetylcysteine Protection in COPD An Alternative Mechanism of Action
To the Editor:
We read with interest the study by Tse et al 1 in a recent issue of CHEST (July 2013). In their study, 1-year treatment with highdose N-acetylcysteine (NAC) resulted in improved small airway function and decreased exacerbation frequency in patients with COPD. The authors proposed that the reduction in COPD exacerbations might be related to antioxidant and antiinfl ammatory effects of NAC, resulting in improved small airway function in COPD. Additionally, they proposed that NAC might reduce exacerbations by inhibiting bacterial adherence to ciliated epithelial cells and by NAC mucolytic effects.
Although we agree with these possibilities, one additional mechanism was not discussed. We propose that a major mechanism of Correspondence NAC-mediated prevention of COPD exacerbations is through restoration of the normal antiviral innate immune response that is suppressed by cigarette smoking and perhaps in COPD.
Cigarette smoking is the major cause of COPD and predisposes patients to severe respiratory tract infections. Respiratory viral infections with rhinoviruses, infl uenza viruses, and respiratory syncytial virus are the main causes of COPD exacerbations, which are associated with disease progression and loss of lung function. 2 Specifi cally, several studies have confi rmed the relationship between cigarette smoking and the risk of infl uenza infection. 3 Infl uenza infections are more severe, with more cough, acute and chronic phlegm production, breathlessness, and wheezing in smokers. 4 The mechanism of increased susceptibility to infections in smokers is likely multifactorial but clearly includes an alteration of immunologic host defenses.
We have demonstrated that cigarette smoke extract (CSE) suppresses host antiviral activity in a human lung model. 5 Thus, cigarette smoke exacerbates the susceptibility of the host to respiratory infectious diseases and the attendant pathology. We found that CSE treatment inhibited infl uenza-induced antiviral cytokine expression in our human model. This is associated with CSE-inhibited messenger RNA and protein expression of the major RNA virus sentinel RIG-I that is important in the antiviral host response. However, inhibition of viral-mediated RIG-I induction by CSE was prevented, and antiviral cytokine responses were restored by NAC. 5 The interactions between host immune responses and infl uenza virus usually determine the outcome of infection. Restoration of these responses by NAC may have been a major mechanism in the decrease in exacerbations demonstrated by Tse et al 1 in patients with COPD.
